Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

36-40 of 61 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status

PlayPhysio Mobile App Study for young people with Cystic Fibrosis

There are many oscillatory PEP devices on the market to use for chest physiotherapy, with strong evidence that they are effective treatments in clearing the lungs. However, they don’t provide the user feedback to confirm that they are using the correct technique or indicate when each blow or treatment session has been completed. As a result this can lead parents to have a lack of confidence in whether their child is completing the physiotherapy session correctly or completely.A father of a CF patient has developed a device alongside the CF team at Cambridge University Hospital called Play Physio, that can be attached to any oscillatory PEP device. The patient can play games which have been designed to encourage the child to comply with the routine and data is collected and sent to the treating clinician in order to monitor compliance. The aims of this study are to look into the safety and efficacy of the Play Physio device and to investigate the effect of the device on compliance. This is a 24 week study in which the CF patients (ages 8-16) use the Play Physio ® device and associated app. Lung function, paper diaries, in app questionnaires and compliance data will all be analysed.

Read more Not Applicable
  • Trial Reference Number

    110395

  • Trial status

    Closed to recruitment - no follow up

  • Therapeutic category

    Other

Experiences of Living with Cystic Fibrosis; The impact on children, young people, adults and their families

Through interviewing both the patient with CF and their families, this study hopes to establish a clearer picture of the effect the condition can have on the individual themselves and on their immediate family, in various aspects of their lives. From this, we hope to understand the key challenges facing these populations to help tailor the development of services.

Read more
  • Trial Reference Number

    95222

  • Length of participation

    1 day

  • Trial status

    Open

  • Therapeutic category

    Behavioral

VX15-770-124 Cystic Fibrosis

This is a Phase 3, 2-part, open-label study designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in subjects with CF who are <24 months of age at treatment initiation and have a CFTR gating mutation on at least 1 allele. Part A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in subjects <24 months of age and to confirm (or adjust if necessary) the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in subjects <24 months of age over 24 weeks.

Read more Phase III
  • Trial Reference Number

    71722

  • Age

    0 - 12

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

The study is a randomized, double-blind, placebo-controlled, study that will be conducted at multiple centers in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation.

  • Trial Reference Number

    108654

  • Age

    18+

  • Therapeutic category

    Restore CFTR Function

Albatross

This is a Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis (CF) with one F508del CFTR mutation and a second gating (class III) mutation. Up to 35 participants are planned to be included in the study for a minimum of 6 weeks and a maximum of 10 weeks. All participants will be at least 18 years of age and have cystic fibrosis with at least one copy of the F508del (Class II) mutation. This study will investigate whether treatment with the corrector GLPG2222 in patients heterozygous for F508del and a gating mutation who are already receiving ivacaftor treatment (standard of care), will result in an additional improvement in CFTR function, as measured by sweat chloride and lung function.

Read more Phase II
  • Trial Reference Number

    88101

  • Age

    18+

  • Trial status

    Completed

  • Therapeutic category

    Restore CFTR Function

36-40 of 61 results for all trials